|
|
|
|
FDA actions in brief, March 2010 (Iprivask, VPRIV, Mirapex ER, Cayston, Menveo, Lamictal XR, Rituxan, Oleptro, Xiaflex, Norvir, Benicar, Crestor)
Desirudin for injection (Iprivask, Canyon) was approved for the prevention of deep vein thrombosis.Velaglucerase alfa for injection (VPRIV, Shire) was approved for the long-term treatment of type 1 Gaucher disease in pediatric and adult patients.
|
|
|
ACC: Chronic Kidney Disease Patients Fare Well in Statin Trial
Explain that this study appears to show safety of rosuvastatin in patients with chronic kidney disease.Explain that there may be differences between patients with chronic kidney disease and those who have progressed to dialysis who may not benefit from...
|
|
|
Rx Abandonment Rate Continues to Rise
The number of prescriptions filled in the retail sector was up 2.7 percent in 2009 from single digit growth in 2008.Thats the good news. The not-so-good news is that the number of scrips being filled for generics is beating branded drugs 2 to 1, and the...
|
|
|
Rx Abandonment Rate Continues to Rise
The number of prescriptions filled in the retail sector was up 2.7 percent in 2009 from single digit growth in 2008.Thats the good news. The not-so-good news is that the number of scrips being filled for generics is beating branded drugs 2 to 1, and the...
|
|
|
New drug could majorly reduce risk of heart disease
The cardiovascular disease rate was down 44 per cent in those using Crestor VANCOUVER (NEWS1130) - A new drug has been approved for use in Canada that can dramatically reduce the risk of heart disease.The head of cardiology at McGill University, Dr.
|
|
|
Shionogi looks to new products, in-house R&D to weather Crestor expiries
Shionogi is aiming to raise its consolidated net sales to 375 billion ($4.Shionogi looks to new products, in-house R&D to weather Crestor expiries.
|
|
|
AstraZeneca's CRESTOR: Health Canada approves new indication
Approval based on JUPITER trial which demonstrated reduction of cardiovascular events by nearly half AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart...
|
|
|
ONGLYZA-metformin combination: FDA accepts NDA for review
Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S.Food and Drug Administrat...Bristol-Myers Squibb to review key accomplishments at meeting with investment communityDuring a meeting with the investment community today, Bristol-Myers...
|
|
|
Clinical Outcomes? Who Needs 'Em
'Welcome to the club.' -- Imaginary text message from Merck (NYSE: MRK) CEO Richard Clark to Abbott Labs (NYSE: ABT) CEO Miles White yesterday.Like Merck's Zetia, Abbott's TriCor has been used by many patients, but neither drug has really been shown to do...
|
|
|
Research and Markets: Atherosclerosis or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
Research and Markets: DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d0f918/atherosclerosis_or) has announced the addition of GlobalData's new report "" to their offering.is an essential source of information and...
|
|
|
Clinical Outcomes? Who Needs 'Em.
"Welcome to the club." -- Imaginary text message from Merck (NYSE: MRK) CEO Richard Clark to Abbott Labs (NYSE: ABT) CEO Miles White yesterday.Like Merck's Zetia, Abbott's TriCor has been used by many patients, but neither drug has really been shown to do...
|
|
|
ACC: Triglycerides Decreased with Rosuvastatin Therapy
University of Pennsylvania School of Medicine.Action Points Explain to interested patients that this study -- which specifically scrutinized the effects of statin therapy on triglycerides -- found that rosuvastatin (Crestor) significantly reduced the...
|
|
|
Crestor, Plavix make new Chinese formulary
China is a promising new market for Big Pharma.And when its government makes a healthcare-related move, the news reverberates throughout the drug industry. Today, it's a good reverberation: China's National Reimbursement Drug List is being updated for the...
|
|
|
FDA Conducts Review Of Study On Abbott's Trilipix
DOW JONES NEWSWIRES The U.S.Food and Drug Administration said it will review data on Abbott Laboratories' (ABT) cholesterol drug Trilipix, which failed to significantly reduce the risk of heart attacks and strokes among diabetics in the so-called Accord...
|
|
|
CORRECT: FDA TO Review Labeling Of Abbott's Trilipix
("FDA Conducts Review of Study On Abbott's Trilipix," published at 11:31 a.m.EDT, incorrectly stated a study's link to Trilipix. The Accord study addressed TriCor, while the Food and Drug Administration is addressing Trilipix.) DOW JONES NEWSWIRES The U.S....
|
|
|
China Drug List Seen Boosting Western Firms' Sales
Chinese plans to broaden the list of medicines eligible for a rebate from July will benefit Western drugmakers such as AstraZeneca and Sanofi-Aventis, according to Morgan Stanley analysts.The National Reimbursement Drug List is being updated for the first...
|
|
|
CORRECT: FDA TO Review Labeling Of Abbott's Trilipix
('FDA Conducts Review of Study On Abbott's Trilipix,' published at 11:31 a.m.EDT, incorrectly stated a study's link to Trilipix. The Accord study addressed TriCor, while the Food and Drug Administration is addressing Trilipix.) DOW JONES NEWSWIRES The U.S....
|
|
|
FDA Conducts Review Of Study On Abbott's Trilipix
DOW JONES NEWSWIRES The U.S.Food and Drug Administration said it will review data on Abbott Laboratories' (ABT) cholesterol drug Trilipix, which failed to significantly reduce the risk of heart attacks and strokes among diabetics in the so-called Accord...
|
|
|
FDA Conducts Review Of Study On Abbott's Trilipix
Dow Jones Newswires DOW JONES NEWSWIRES The U.S.Food and Drug Administration said it will review data on Abbott Laboratories' (ABT) cholesterol drug Trilipix, which failed to significantly reduce the risk of heart attacks and strokes among diabetics in the...
|
|
|
CORRECT: FDA TO Review Labeling Of Abbott's Trilipix
("FDA Conducts Review of Study On Abbott's Trilipix," published at 11:31 a.m.EDT, incorrectly stated a study's link to Trilipix. The Accord study addressed TriCor, while the Food and Drug Administration is addressing Trilipix.) DOW JONES NEWSWIRES The U.S....
|
|
|
FDA Conducts Review Of Study On Abbott's Trilipix
Dow Jones Newswires DOW JONES NEWSWIRES The U.S.Food and Drug Administration said it will review data on Abbott Laboratories' (ABT) cholesterol drug Trilipix, which failed to significantly reduce the risk of heart attacks and strokes among diabetics in the...
|
|
|
China drug list seen boosting Western firms' sales
LONDON (Reuters) - Chinese plans to broaden the list of medicines eligible for a rebate from July will benefit Western drugmakers such as AstraZeneca and Sanofi-Aventis, according to Morgan Stanley analysts.The National Reimbursement Drug List is being...
|
|
|
China drug list seen boosting Western firms' sales
Tools and articles to help you manage your finances better The National Reimbursement Drug List is being updated for the first time since 2004 with many Western drugs added to the category that entitles patients to a rebate of up to 50 percent.New entrants...
|
|
|
China drug list seen boosting Western firms' sales
LONDON (Reuters) - Chinese plans to broaden the list of medicines eligible for a rebate from July will benefit Western drugmakers such as AstraZeneca and Sanofi-Aventis, according to Morgan Stanley analysts.The National Reimbursement Drug List is being...
|
|
|
China drug list seen boosting Western firms' sales
43 mins ago LONDON (Reuters) Chinese plans to broaden the list of medicines eligible for a rebate from July will benefit Western drugmakers such as AstraZeneca and Sanofi-Aventis, according to Morgan Stanley analysts.The National Reimbursement Drug List is...
|
